Back to search results
NCT07388667

A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)

Active, Not Recruiting
PHASE1Ages 18–60InterventionalBasic science
Merck Sharp & Dohme LLC
~120 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:MK-4082Placebo

At a glance

Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants Who Experience an Adverse Event (AE)
Measured over Up to approximately 98 Days
+1 more outcome measured

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

5 sites across 4 states
California2
Florida1
Missouri1
New Jersey1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is in good health
Has body mass index (BMI) between 25 and 40 kg/m\^2, inclusive. Participants must weigh at least 60 kg

Exclusion

has a history of previous surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal (GI) surgery that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss (including LAP-BAND®), as well as clinically significant GI disorders (eg, peptic ulcers, severe gastroesophageal reflux disease)
has an individual or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2

What this trial measures

  • Number of Participants Who Experience an Adverse Event (AE)Up to approximately 98 Days

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

  • Number of Participants Who Discontinue Study Treatment Due to an AEUp to approximately 84 Days

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.